Multi-Modality Platform for Undruggable Targets
Genesis Therapeutics
This is really a statement about platform breadth, not just molecule count. Genesis starts with classic small molecules, but every added modality lets the same target biology be attacked with a different chemical tool. That matters because many disease proteins fail not for lack of biological relevance, but because they lack a deep pocket where a standard drug can grab on, or because the job requires organizing several molecules at once inside a protein complex.
-
Macrocycles, constrained peptides, and covalent compounds are useful when a target presents a broad, flat contact surface instead of an enzyme like pocket. Those formats can cover more surface area, lock into shape, or form stronger attachment points, which expands the set of protein-protein interactions that medicinal chemists can realistically work on.
-
Protein degraders widen the map again because the goal is not just to block a protein, but to bring it into a three part complex that marks it for destruction. That design problem depends on modeling target, binder, linker, and E3 ligase together, which fits Genesis’s emphasis on three dimensional and multibody interaction modeling.
-
This is also where competitive positioning sharpens. Isomorphic is already using the same core structure and interaction stack across small molecules, antibodies, peptides, and molecular glues, and its J&J deal spans multiple modalities. Genesis pursuing the same direction would move it closer to broader R&D budgets instead of being limited to narrow small molecule discovery work.
The next step is a shift from being a good small molecule engine to being a general purpose difficult target engine. If Genesis shows that GEMS can repeatedly design across degraders, glues, and other nonstandard chemistries, it can go after more partner programs, more internal assets, and a larger share of the targets that pharma teams still cannot drug with conventional chemistry.